Ultimovacs is a clinical-stage biotechnology company developing novel immunotherapies against cancer. The product candidate UV1 is an off-the-shelf therapeutic cancer vaccine designed to enhance the benefits of immunotherapy and improve cancer treatment efficacy for patients. UV1 triggers an immune response against the shared cancer antigen telomerase, a target present in 85-90% of all cancer indications across disease stages.
Ultimovacs is investigating the safety and efficacy of UV1 in a wide-ranging clinical development program including various cancer indications and different immunotherapy combinations. The ongoing Phase II program comprises five randomized clinical trials in melanoma, mesothelioma, head and neck cancer, ovarian cancer, and non-small cell lung cancer. More than 650 patients in the U.S., Europe, and Australia are being enrolled in all Phase I and Phase II trials in the current program.
UV1 is designed as a convenient off-the-shelf product with a long shelf life, and is easy to use with simple intradermal administration. It is a patented, proprietary technology owned by Ultimovacs.
More than 300 patients have already received treatment with UV1 in clinical trials, and no toxicity or safety concerns have been reported to date.
Furthermore, Ultimovacs is developing a novel conjugation technology, initially formed to support the expansion of our vaccine pipeline. With the objective of driving value and future pipeline growth, this flexible conjugation technology has the potential to be broadly applicable to a variety of therapeutic modalities, such as innovative drug conjugates with favorable pharmacological properties, and in multiple disease areas.
Ultimovacs was established in 2011, and is headquartered at the Oslo Cancer Cluster Innovation Park in Oslo, Norway, and also has an office in Uppsala, Sweden. The company and its proprietary technology are based on pre-clinical and clinical research on immunotherapies conducted at the Oslo University Hospital. The company is a limited public liability company listed on the Oslo Stock Exchange in Norway. Ultimovacs is listed on the Euronext Oslo Stock Exchange (OSE:ULTI).
For more information, download our company presentation from the Presentations and Publications page.
For patients
Ultimovacs is developing a new type of cancer treatment. We are currently evaluating the safety and efficacy. We have not secured regulatory approval and so we are not able to use the treatment outside of our clinical trial program.
If you are a cancer patient and wish to participate in a clinical trial, you should discuss this with the physician responsible for your treatment.